Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Revenue Recognition, PPE, Licensing and Research (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2014 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) agreement shares	Sep. 30, 2017 USD ($) shares	Dec. 31, 2017 USD ($)
Revenue Recognition
Number of distribution and license agreements | agreement				2
Customers average payment term				30 days
Distributors average payment term				45 days
Impairment losses				$ 0
Bad-debt expense		$ 0	$ 0	0	$ 0
Contract assets		0		0
Revenue performance obligation		15,005,000		$ 15,005,000
Remaining performance obligation practical expedient				true
Research and Product Development
Product development and research costs		808,192	1,304,658	$ 4,033,494	4,195,003
Investments Available for Sale
Fair value of investments		13,410,151		13,410,151		$ 24,648,459
Realized gains		2,411	57	6,050	57
Research and Development
Research and Development Expense		808,192	1,304,658	4,033,494	4,195,003
Stock-Based Compensation
Compensation expense (in dollars)		614,583	1,636,507	$ 2,425,919	$ 6,026,578
Loss Per Share
Securities excluded from diluted loss per share calculation | shares				9,341,855	7,806,501
Baxter Healthcare Organization
Revenue Recognition
Upfront payment	$ 20,000,000
Deferred drug license revenue		500,000		$ 1,500,000	$ 1,500,000
Revenue performance obligation		11,732,000		$ 11,732,000
Remaining performance obligation practical expedient				true
Licensing Fees
Useful life	10 years
Stock options
Stock-Based Compensation
Compensation expense (in dollars)		427,944	1,071,653	$ 967,377	3,275,339
Restricted stock awards
Stock-Based Compensation
Compensation expense (in dollars)		20,222	$ 564,854	1,292,125	$ 2,751,239
Concentrate Products [Member]
Revenue Recognition
Reserve for returns		$ 0		$ 0		$ 0